Full-Life Technologies Secures $10M Seed Funding to Advance Innovative Targeted Radiopharmaceuticals for Global Cancer Patients

On December 21, Full-Life Technologies announced the completion of a $10 million seed financing round. The investment will be used to advance the development of its product pipeline and build its nuclear technology platform, which aims to address supply chain challenges in nuclear medicine. This round was co-led by Chengwei Capital and Geding Ventures.

“Nuclear medicine represents one of the most effective and compelling opportunities in targeted cancer therapy, with the potential to deliver substantial clinical value to patients worldwide,” said Dr. Huang Zhonglian, Co-founder and Chief Operating Officer of Full-Life Technologies. “Full-Life is positioned as the only company developing end-to-end solutions for radioligand therapy, with a vision to integrate cutting-edge production and logistics technologies with frontier drug discovery approaches.”

In recent years, nuclear medicine has experienced a renaissance, achieving significant clinical and commercial validation for some of the most challenging cancers. Nevertheless, it remains an underinvested field, and additional drug discovery efforts are essential to rapidly deliver new concepts, modalities, and therapies to patients worldwide. Given the nature of radioisotopes, nuclear medicine faces unique supply chain, production, and logistical challenges. Full-Life Technologies was established by a team of experts with extensive experience in nuclear medicine, physics, and logistics, together with global leaders in drug R&D, to address these challenges facing patients.

Full-Life Technologies is a fully integrated, international radiopharmaceutical company headquartered in Shanghai, with operations extending across Europe. Our mission is: Unlocking the Power of Half-Life, Bringing Hope for a Full Life to Patients Worldwide! We are building a full value chain encompassing the production, research, development, and commercialization of radioligands to deliver greater clinical benefits to patients. Our core platforms are designed to address two critical challenges in contemporary radiopharmaceuticals: 1) the capacity to produce radioisotopes of high quality and sufficient quantity to meet future demand, and 2) an innovative translational and biological research platform for next-generation radiopharmaceutical therapies. Our team comprises seasoned entrepreneurs and scientists with proven track records in building biopharmaceutical companies and advancing radioisotope research and clinical development. From Half-Life to Full Life.

Becoming Capital, founded in 1999, is one of the earliest international venture capital firms to invest in Chinese domestic enterprises. Adhering to a distinctive investment philosophy of selective and high-conviction investments, heavy capital commitment, and identifying and nurturing unicorns, it has established China’s first evergreen fund, characterized by substantial capital resources and perpetual duration.

Over the past two decades, Chengwei Capital has invested in high-end intelligent manufacturing, the internet, semiconductors, enterprise services, and healthcare, with a cumulative total investment exceeding US$2 billion. The firm has invested in more than 100 technology companies in China, 14 of which have successfully gone public. Currently, Chengwei Capital has established an investment portfolio focused on four key sectors: industrial internet, consumption upgrading, high-end intelligent manufacturing, and healthcare. Chengwei Capital will continue to align its investments with core industries, collaborate synergistically with portfolio companies, and pursue mutual growth.

Gordian is a global life sciences venture capital firm focused on incubating companies with exceptionally high technological barriers. The Gordian team comprises successful entrepreneurs who are dedicated to serving as true co-founders of each company they operate and incubate. Headquartered in Boston, Gordian maintains an office in China.